Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Research analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for shares of Legend Biotech in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.06 for the quarter, down from their prior estimate of $0.12. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.14 EPS, Q4 2026 earnings at $0.26 EPS and FY2027 earnings at $2.28 EPS.

Several other equities analysts have also recently weighed in on LEGN. Oppenheimer started coverage on Legend Biotech in a research note on Wednesday, January 7th. They set an “outperform” rating and a $75.00 target price on the stock. Cantor Fitzgerald lowered their price target on shares of Legend Biotech from $75.00 to $74.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Jefferies Financial Group reiterated a “buy” rating and set a $69.00 price objective on shares of Legend Biotech in a report on Tuesday, March 10th. Truist Financial set a $70.00 target price on Legend Biotech in a research report on Tuesday, March 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Legend Biotech in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Legend Biotech has an average rating of “Moderate Buy” and a consensus target price of $58.31.

Legend Biotech Stock Down 2.9%

LEGN opened at $18.55 on Wednesday. The firm has a market capitalization of $3.43 billion, a P/E ratio of -23.19 and a beta of 0.07. The stock has a fifty day moving average of $19.29 and a 200-day moving average of $25.93. Legend Biotech has a 12-month low of $16.24 and a 12-month high of $45.30.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, March 10th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.18. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The business had revenue of $306.30 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period last year, the firm posted $0.07 earnings per share. The firm’s quarterly revenue was up 64.2% compared to the same quarter last year.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors have recently modified their holdings of LEGN. Clearstead Advisors LLC grew its stake in Legend Biotech by 76.5% in the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after buying an additional 367 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after acquiring an additional 662 shares during the period. OFI Invest Asset Management grew its position in shares of Legend Biotech by 102.6% in the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock valued at $40,000 after purchasing an additional 622 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Legend Biotech during the 2nd quarter worth about $78,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Legend Biotech during the 3rd quarter valued at approximately $104,000. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.